Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acusphere, Inc.
Acusphere, Inc. Announces Resignation of Richard Walovitch
January 23rd, 2009
Acusphere, Inc. (NASDAQ: ACUS) announced that Dr. Richard Walovitch, Senior Vice President of Clinical Research, has resigned to pursue another opportunity. His resignation, effective January 9, 2009, follows an 11 year career with Acusphere, in which he oversaw the Company’s clinical trials for its lead product candidate, ImagifyTM (Perflubutane Polymer Microspheres) for Injectable Suspension, a cardiovascular drug for the detection of coronary artery disease, which addresses a potential $2 billion U.S. marketplace. Said Dr. Walovitch, “I am very proud to have been associated with Acusphere’s efforts on behalf of Imagify, and our work to demonstrate its benefits to...
Source: Health Business Week (2009-01-23)
|
